Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.46 |
| ▸ | MAOA | P21397 | 6/20 | 0.37 |
| ▸ | MAOB | P27338 | 6/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18634519 | 0.92 | GRM5 (0.45) | GRM5MAOAMAOBPRKCIMEN1 | |
| SCHEMBL19566332 | 0.87 | GRM5 (0.49) | GRM5MAOAMAOBPRKCIMEN1 | |
| SCHEMBL14979694 | 0.85 | GRM5 (0.47) | GRM5MAOAMAOBPRKCIMEN1 | |
| SCHEMBL17332079 | 0.83 | GRM5 (0.44) | GRM5MAOAMAOBPRKCIMEN1 | |
| SCHEMBL17332094 | 0.82 | GRM5 (0.45) | GRM5MAOAMAOBPRKCIMEN1 | |
| SCHEMBL19548369 | 0.82 | MAOB (0.46) | GRM5MAOAMAOBPRKCIMEN1 | |
| SCHEMBL17332161 | 0.82 | GRM5 (0.44) | GRM5MAOAMAOBPRKCIMEN1 | |
| SCHEMBL17332147 | 0.82 | GRM5 (0.44) | GRM5MAOAMAOBPRKCIMEN1 | |
| SCHEMBL17332081 | 0.80 | GRM5 (0.53) | GRM5MAOAMAOBPRKCIPGR | |
| SCHEMBL17343502 | 0.77 | MAOB (0.40) | MAOAMAOBPRKCIMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210053981-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
| EP-3778606-A2 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2021-02-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053981-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | GRM5 4231/4885MAOA 3181/4885MAOB 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.